Opinion|Videos|November 18, 2026

Ponatinib in Ph+ ALL: Translating Clinical Value Into Treatment Decisions

Before the order goes in: is ponatinib right for the patient in front of you, and can they get it?

In “Ponatinib in Ph+ ALL: Translating Clinical Value Into Treatment Decisions,” Maples asks Griffin how he confirms that ponatinib is the right treatment for a patient with Ph+ ALL and how he turns that decision into action.

Griffin, an associate clinical professor and hematology and stem cell transplant pharmacist at the University of California, Irvine, says his first concern is whether the patient can actually receive ponatinib. TKIs are not on his institution’s formulary, so starting one requires a nonformulary request. That request is routinely approved and covers the inpatient stay, but he is already planning for access after discharge.

He also considers patient-specific risks: underlying risk factors or a history of clotting events, which TKI the patient’s insurer prefers, and whether a high copay will require extra help.

Griffin stresses tying ponatinib to response milestones. With TKI-plus-chemotherapy regimens, 2 disease assessments matter most for long-term outcomes: the one after induction and the one before allogeneic stem cell transplant. Reaching a complete molecular response with MRD negativity after induction sets patients up for the best outcomes, whatever consolidation or maintenance approach follows. Making sure those assessments happen at the right time is one way pharmacists track whether the treatment is working.

Maples adds that tracking these milestones also matters when patients start on another TKI, because new mutations can make a switch necessary. Griffin notes that the ponatinib dose will likely change once a patient achieves a complete molecular response. Pharmacists need to catch that change when the prescription is refilled or reissued.

Our next episode, “Case Discussion: Selecting and Initiating Therapy in a Newly Diagnosed Patient,” applies these considerations to a patient with a high disease burden.


Related to this article